Insights

Acquisition Advantage Qpex Biopharma is now a Shionogi Group Company, which can accelerate access to global distribution channels, regulatory expertise, and strategic partnerships to expand sales opportunities for their antibiotic resistance programs.

Advanced Portfolio The company focuses on β-lactamase inhibitors and QPX7728-based products, offering a strong foothold in next‑generation antibiotic combinations that can appeal to hospitals and health systems aiming to combat multi-drug resistant infections.

Public-Private Ties History of BARDA collaborations and public‑private partnerships signals a track record of government-funded programs, which can be leveraged to co‑fund trials, expand access programs, and secure likely procurement opportunities.

Clinical Readiness With prior Phase data presentations and ongoing development of oral and IV formulations, there are clear near-term touchpoints for KOL engagements, clinical trial supply deals, and early access discussions with hospital networks.

Global Licensing Existing licensing agreements in Greater China and international interest from Brii Bio indicate potential for regional co‑development and distribution deals, enabling rapid market-entry collaborations in multiple regions.

Similar companies to Qpex Biopharma, Inc.

Qpex Biopharma, Inc. Tech Stack

Qpex Biopharma, Inc. uses 8 technology products and services including iCIMS, Amazon Web Services, Microsoft SharePoint, and more. Explore Qpex Biopharma, Inc.'s tech stack below.

Media & News

Qpex Biopharma, Inc.'s Email Address Formats

Qpex Biopharma, Inc. uses at least 3 email formats:
Qpex Biopharma, Inc. Email FormatsExamplePercentage
FLast@qpexbio.comJDoe@qpexbio.com
89%
First.Last@qpexbio.comJohn.Doe@qpexbio.com
5%
LastFirst@qpexbio.comDoeJohn@qpexbio.com
6%

Frequently Asked Questions

What is Qpex Biopharma, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Qpex Biopharma, Inc.'s official website is qpexbio.com and has social profiles on LinkedIn.

How much revenue does Qpex Biopharma, Inc. generate?

Minus sign iconPlus sign icon
As of October 2026, Qpex Biopharma, Inc.'s annual revenue is estimated to be $10M - $25M.

What is Qpex Biopharma, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Qpex Biopharma, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Qpex Biopharma, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2026, Qpex Biopharma, Inc. has approximately 36 employees across 2 continents, including North America and Asia. Key team members include Vice President: M. L. Explore Qpex Biopharma, Inc.'s employee directory with LeadIQ.

What industry does Qpex Biopharma, Inc. belong to?

Minus sign iconPlus sign icon
Qpex Biopharma, Inc. operates in the Biotechnology Research industry.

What technology does Qpex Biopharma, Inc. use?

Minus sign iconPlus sign icon
Qpex Biopharma, Inc.'s tech stack includes iCIMS, Amazon Web Services, Microsoft SharePoint, Wix, WordPress, SAP, Google Cloud and Microsoft Teams.

What is Qpex Biopharma, Inc.'s email format?

Minus sign iconPlus sign icon
Qpex Biopharma, Inc.'s email format typically follows the pattern of FLast@qpexbio.com. Find more Qpex Biopharma, Inc. email formats with LeadIQ.

How much funding has Qpex Biopharma, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2026, Qpex Biopharma, Inc. has raised $63M in funding. The last funding round occurred on May 30, 2024.

When was Qpex Biopharma, Inc. founded?

Minus sign iconPlus sign icon
Qpex Biopharma, Inc. was founded in 2018.
Qpex Biopharma, Inc. logo

Qpex Biopharma, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Qpex Biopharma, Inc. is a San Diego‑based biotechnology company that concentrates on infectious diseases with a focus on drug resistance. It develops and advances treatments designed to overcome multi-drug resistance, aiming to improve patient care in a sustainable way and to deliver the right therapies to the right patients in the right settings. Over the past decade, the team has helped bring four antibiotic products to regulatory approvals and has a history of collaborations with public-private partners, including BARDA.

In 2023, Qpex Biopharma became part of Shionogi, Inc., operating as a Shionogi Group Company. The company has engaged in international partnerships to advance anti-infective programs, including a 2019 licensing arrangement with Brii Bio to develop BRII-693 and QPX7728-based products in Greater China.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $63M

    Qpex Biopharma, Inc. has raised a total of $63M of funding over 4 rounds. Their latest funding round was raised on May 30, 2024 as a Grant.

  • $10M - $25M

    Qpex Biopharma, Inc.'s revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.